REFERENCES
- Abdo-Rabbo A, Bassili A&, Atta H. (2005). The quality of antimalarials available in Yemen. Malaria Journal, 4, 28.
- Alfadl AA, Abdoon S, Elamin M&, Elnabi NG. (2006). Quality of antimalarail drugs in Sudan: results of post-marketing surveillance. Sudan Journal of Public Health, 1, 108–111.
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D&, White NJ. (2009). Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361, 455–467.
- European Pharmacopoeia. (2008). European Directorate for the Quality of Medicines —Council of Europe (COE). Strasbourg: COE.
- Falade CO, Ogundele AO, Yusuf BO, Ademowo OG&, Ladipo SM. (2008). High efficacy of two artemisinin-based combinations (artemether–lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Tropical Medicine and International Health, 13, 635–643.
- Green MD. (2006). Antimalarial drug resistance and the importance of drug quality monitoring. Journal Postgraduate Medicine, 52, 288–290.
- Levi L, Walker GC&, Pugsley LI. (1964). Quality control of pharmaceuticals. Canadian Medical Association Journal, 91, 781–785.
- Maponga C&, Ondari C. (2003). The Quality of Antimalarials: A Study in Selected African Countries. Geneva: WHO.
- Ofonaike JO, Enato EFO&, Okhamafe AO. (2007). A study of the pharmaceutical quality of chloroquine and paracetamol products sold in a major Nigerian ‘market’. African Journal of Health Sciences, 14, 164–170.
- Ogwal-Okeng JW, Owino E&, Obua C. (2003). Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. African Journal of Health Sciences, 3, 2–6.
- Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V&, Okonkwo P. (2009). Quality of anti-malarial drugs provided by public and private healthcare providers in Southeast Nigeria. Malaria Journal, 8, 22.
- Ten HM. (2003). Health risks of counterfeit pharmaceuticals. Drug Safety, 26, 991–997.
- United States Pharmacopeia. (2006). United States Pharmacopeia Convention. Rockville, MD: USP.
- White NJ. (2004). Antimalarial drug resistance. Journal of Clinical Investigation, 113, 1084–1092.
- World Health Organization. (2001). Surveillance and Response Monitoring Antimalarial Drug Resistance. Geneva: WHO.
- World Health Organization. (2008). World Malaria Report 2008. Geneva: WHO.
- World Health Organization. (2009). World Malaria Report 2009. Geneva: WHO.